Erinacine A

Erinacine A is a cyathane-type diterpenoid isolated from solid-state or liquid cultures of Hericium erinaceus mycelium, where it typically accumulates as the dominant erinacine. Its defining property is the induction of NGF biosynthesis in glial and neuronal cell models, which drives downstream neurite outgrowth and supports the basal forebrain cholinergic system. Because of its compact, lipophilic scaffold, erinacine A is reported to cross the blood brain barrier and to raise NGF within the locus coeruleus and hippocampus of treated rats, a pharmacokinetic feature that distinguishes the mycelial erinacines from the peripherally acting fruiting-body hericenones ^[1][7].

In disease models, erinacine A-enriched mycelium attenuated cerebral amyloid-beta plaque burden, raised the NGF to proNGF ratio, and promoted hippocampal neurogenesis in APPswe/PS1dE9 transgenic mice ^[2]. In a global ischemia-reperfusion stroke model it reduced infarct volume and lowered interleukin-1-beta, interleukin-6 and tumor necrosis factor-alpha through suppression of iNOS, p38 MAPK and nitrotyrosine ^[3]. In MPTP models of Parkinsonism, erinacine A-rich mycelium restored striatal dopamine and boosted endogenous antioxidant enzymes such as catalase and superoxide dismutase ^[4]. In aging mice fed a high-fat high-sucrose diet it reversed spatial-learning deficits while lowering neuroinflammatory cytokines and improving metabolic markers ^[6].

Beyond the nervous system, erinacine A shows antitumor activity: in human colorectal DLD-1 cells it triggered extrinsic apoptosis via TNFR, Fas and Fas ligand upregulation through a JNK/p300/NF-kappaB-p50 pathway with associated histone acetylation ^[5]. A 2026 review summarizing preparation, biological activity and biosynthesis frames erinacine A as a leading fermentation-derived neurotrophic candidate whose main translational bottleneck is low natural yield and high production cost ^[1].

Extensive preclinical evidence; no isolated-compound human trials

Erinacine A is consumed as a component of standardized Hericium erinaceus mycelium supplements, and repeated-dose toxicology of erinacine A-enriched mycelium in rodents has not flagged major organ toxicity at nutritional doses. Human safety data derive from mycelial and fruiting-body products rather than the purified diterpenoid; reported adverse effects are limited to occasional mild gastrointestinal discomfort and rare skin reactions in sensitive individuals. Because it modulates growth-factor and apoptosis pathways, isolated high-dose use remains investigational and is not established for pregnancy, lactation, or concurrent oncologic therapy.

Erinacines were first characterized from Hericium erinaceus mycelium by Japanese natural-product chemists in the 1990s during a systematic search for small-molecule NGF inducers, complementing the earlier discovery of the fruiting-body hericenones. Erinacine A emerged as the most abundant and centrally active member of the series. From the 2010s onward, groups in Taiwan (notably at Grape King Bio and Chang Gung institutions) advanced erinacine A-enriched mycelium through models of Alzheimer disease, Parkinson disease, stroke and depression, and by 2026 fermentation-optimization reviews positioned it as a scalable neurotrophic lead.

Within the nootropic and medicinal-mushroom community, erinacine A is regarded as the active principle that best explains the cognitive reputation of Lion's Mane mycelium products, and premium supplements are frequently standardized to an erinacine A percentage. Researchers view it as one of the most promising natural NGF inducers, tempered by the fact that nearly all efficacy evidence remains preclinical and that potency depends heavily on cultivation and extraction.